LVOCheck

LVOne is a rapid diagnostic test for Large Vessel Occlusion (LVO) stroke detection, delivering results in minutes with 95% accuracy. Using a proprietary combination of D-dimer and GFAP biomarkers in a lateral flow format, it enables emergency teams to identify stroke type quickly without additional equipment. Validated across NHS stroke centers, the test supports faster treatment decisions in ambulance and urgent care settings.

A lateral flow diagnostic test for detecting Large Vessel Occlusion (LVO) stroke using a proprietary combination of D-dimer and GFAP biomarkers. The test is portable, stable at room temperature, and designed for use in ambulances and urgent care settings without additional equipment. Clinical validation was conducted across 6 NHS stroke hospitals in partnership with Newcastle University.

LVOne is a rapid diagnostic test for detecting Large Vessel Occlusion (LVO) stroke using a novel combination of D-dimer and GFAP biomarkers. Portable and stable at room temperature, it delivers results in minutes without additional equipment, enabling faster clinical decision-making in ambulances and urgent care settings. Validated across 500+ patients in NHS stroke hospitals.

LVOne is a lateral flow diagnostic test that detects Large Vessel Occlusion (LVO) stroke using D-dimer and GFAP biomarkers, delivering results in minutes without additional equipment. Designed for use in ambulances and urgent care settings, it enables rapid clinical decision-making to accelerate access to life-saving thrombectomy treatment. Validated across NHS stroke centers, the test is portable, room-temperature stable, and requires minimal training.

Point-of-care diagnostic test for detecting ischemic stroke and traumatic brain injury based on biomarkers.

Automated immunoassay system for rapid blood-based diagnosis of traumatic brain injury using dual biomarkers (GFAP and UCH-L1). The VEUS platform delivers results within 15-50 minutes with high sensitivity and multiplexing capability, utilizing magnetic particle technology for accurate point-of-care neurological assessment.

VEUS is a fully automated diagnostic system for rapid detection of traumatic brain injury using blood-based biomarkers GFAP and UCH-L1. The platform employs magnetic particle immunoassay technology to deliver results within 15-50 minutes with high sensitivity and accuracy.

POCT for assessing coagulation and thrombotic risk in stroke and cerebrovascular disease patients. Guides anticoagulation therapy and prevents recurrent cerebrovascular events. Applicable in neurology and stroke units.

In vitro diagnostic reagent for neurological injury assessment. Supports rapid detection of brain injury biomarkers.

Diagnostic test kit for measurement of biomarkers associated with cerebrovascular disease and stroke risk. Facilitates assessment of neurological and cerebrovascular health status.

Epigenetic-based diagnostic test for early detection of cerebrovascular disease and stroke risk. Developed in collaboration with Beijing Tiantan Hospital, this test supports stroke prevention initiatives. The product integrates findings from a large-scale stroke cohort study.

A blood-based diagnostic kit designed for the rapid and accurate identification of traumatic brain injury using dual biomarker detection with high sensitivity and specificity. The kit detects GFAP and UCH-L1 proteins that leak into bloodstream following head trauma.